TEST:

Sel-Cap™ Lung Cancer Panel

Sel-Cap™ Lung Cancer Panel is a next-generation sequencing (NGS)-based liquid biopsy assay designed to detect clinically relevant genetic mutations in patients with non-small cell lung cancer (NSCLC). It uses a digital enrichment NGS platform to analyze circulating tumor DNA (ctDNA) from plasma, enabling non-invasive detection of key driver and resistance mutations, particularly in the EGFR gene (e.g., exon 19 deletion, L858R, T790M).